Imperial Innovations Limited

Ge Healthcare Limited

Other

Cancer Research Technology Limited

Hammersmith Imanet Limited

Imperial College

Eric Ofori Aboagye

Lisa Iddon

Matthias Eberhard Glaser

Federica Pisaneschi

Timothy H Witney

Quang-De Nguyen

Alan Cuthbertson

Erik Arstad

Sajinder Kaur Luthra

Bard Indrevoll

Peter Brian Iveson

Giampaolo Tomasi

Wendy Vigushin, Legal Representative

David Michael Vigushin

Graham Smith

Julius Leyton

Sajinker Kaur Luthra

Maciej Kaliszczak

Sebastian Trousil

Susan Hoppmann

Duncan Robert R Hiscock

Quang-Dé Nguyen

The present invention pertains generally to the field of imaging compounds, and more specifically to certain 2,2-dialkyl radionuclide-labelled carboxylic acids suitable for PET, SPECT and/or DNP imaging. Also described are used of such compounds in the imaging of inter alia, cancer tumours, metastasis, Alzheimer's disease and multiple sclerosis.

Labelled carboxylic acids and their uses in molecular imaging

A method of use of an isolated polypeptide conjugated with a radionuclide, wherein the isolated polypeptide binds specifically to HER2, or a variant thereof is described. The method is for monitoring the response to HSP90 inhibition and comprises the use of the isolated polypeptide conjugated with 18F. The application also describes the use of an isolated polypeptide conjugated with 18F, wherein the isolated polypeptide binds specifically to HER2 or variants thereof, as an imaging agent to monitor uptake thereof to measure HSP90 inhibition.

HER2 polypeptides useful for imaging and monitoring tumors and cancers

The present invention pertains generally to the field of imaging compounds, and more specifically to certain 2,2-dialkyl radionuclide-labelled carboxylic acids suitable for PEWT, SPECT and/or DNP imaging. Also described are uses of such compounds in the imaging of, inter alia, cancer tumors, metastasis, Alzheimer's disease and multiple sclerosis.

Novel radiotracer(s) for Positron Emission Tomography (PET) imaging are described. Novel radiotracer(s) for Positron Emission Tomography (PET) imaging of neuorendocrine tumors are described. Specifically the present invention describes novel [18F]Fluoroethyltriazol-[Tyr3]Octreotate analogs; in particular those that target somatostatin receptors found on the cell surface of gastroenteropancreatic neuorendocrine tumors. The present invention also describes intermediate(s), precursor(s), pharmaceutical composition(s), methods of making, and methods of use of the novel radiotracer(s).

Radiolabelled octreotate analogues as PET tracers

Isatin 5-sulfonamide derivatives, pharmaceutical compositions comprising the derivatives, their use as molecular imaging agents, their use for the diagnosis or treatment of diseases or disorders associated with dysregulation of apoptosis, methods for synthesizing the derivatives, methods for the molecular imaging of caspase activity and apoptosis, and methods of assessing the therapeutic effect of a test substance on caspase activity are disclosed.

Isatin derivatives for use as in vivo imaging agents

There is provided a compound of formula (I) wherein R, R, R, Xto X, a, b and c have meanings given in the description, which compounds are useful as, or are useful as prodrugs of, inhibitors of HDAC enzyme activity, and thus, in particular, in the treatment of conditions where inhibition of HDAC enzyme activity is required. 

Compounds and uses thereof

Growing community of inventors

London, United Kingdom

Eric Ofori Aboagye